Aureka

Based in Laguna Hills, US, and established in 2023, Aureka Biotechnologies, Inc. trading under the name Aureka, was founded to provide drug discovery services for complex targets in the pharmaceutical industry. The company was established by CEO Dr. Weian Zhao, with a core team focused on integrating microfluidic systems, synthetic biology, and artificial intelligence.

Since its inception, the firm has advanced from platform development to large-scale molecular design and has established partnerships with several multinational pharmaceutical companies. In April 2026, the company raised USD 35 million in series A+ funding led by HSG. The company works with multinational pharmaceutical and biotechnology firms to provide its proprietary AuraIDE™ intelligent antibody design platform. Its technology solutions leverage high-throughput microfluidic systems to characterize complex drug functions, such as agonistic activity, endocytosis, and brain permeability, delivering commercial-ready pipeline data packages (including pre-CMC and pre-toxicology data) within 9 to 12 months.

The company’s internal pipeline focuses on antibody drug development for cardiovascular, metabolic, immunological, and central nervous system diseases. The company generates revenue from B2B business development transactions and project collaborations with pharmaceutical and biotechnology companies. This includes fees for the delivery of differentiated functional molecules designed by AI agents and the provision of comprehensive drug pipeline data packages. The company will use the latest series A+ funding to advance the construction of its proprietary functional antibody design platform, AuraIDE, enhance the capabilities of its base models and AI agents, and improve high-throughput experimental facilities to streamline drug development from molecular design to translational implementation.